The startup Nevro Corp. managed to convince FDA that its Senza neurostimulation device is superior to older comparable technologies. A clinical trial sponsored by the company found that nearly nine out of 10 patients preferred the Senza device to a traditional spinal cord stimulator. One of the key selling points of the device is that it is designed to relieve chronic pain without triggering a tingling sensation known as paraesthesia.
Nevro has been aggressive in obtaining intellectual property for the device, which is now covered by 52 U.S. patents.
Help employers find you! Check out all the jobs and post your resume.
